Effects of TA-65, a Telomerase Activator on Metabolic Syndrome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02531334 |
Recruitment Status :
Completed
First Posted : August 24, 2015
Last Update Posted : October 10, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metabolic Syndrome X | Dietary Supplement: TA-65 | Not Applicable |
Short telomeres are strongly linked to increased risk of cardiovascular disease and diabetes, indications where tissue aging and senescence play significant roles. Shorter leukocyte telomere length has been linked to impaired glucose tolerance, Type 2 Diabetes, and coronary heart disease. Telomere length and telomerase activity have been shown to be significantly lower in CAD patients. Telomere length may play an important role in predicting cardiovascular disease and diabetes. TA-65 may not only ameliorate the symptoms associated with these disease states, but be a preventive measure as well.
In this study, the researchers will investigate whether telomerase activator (TA)-65 can also improve the metabolic dysregulations associated with metabolic syndrome including oxidative stress, inflammation, high blood pressure and dyslipidemias.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Effects of TA-65, a Telomerase Activator on Metabolic Syndrome |
Study Start Date : | August 2015 |
Actual Primary Completion Date : | December 2017 |
Actual Study Completion Date : | June 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: TA-65
TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
|
Dietary Supplement: TA-65
2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo. |
Placebo Comparator: Placebo
Placebo will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
|
Dietary Supplement: TA-65
2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo. |
- Plasma insulin [ Time Frame: 27 weeks ]The supplement is expected to decrease insulin resistance in metabolic syndrome patients
- Plasma HDL cholesterol [ Time Frame: 27 weeks ]The supplement is expected to increase plasma HDL cholesterol
- Blood pressure [ Time Frame: 27 weeks ]The supplement is expected to decrease blood pressure

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 32 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 32 to 70 years
- Men and women
- Proficiency in English
- Postmenopausal women, or women of childbearing age (premenopausal) must be using some form of contraception or have had a hysterectomy
-
Classification of metabolic syndrome according to the Adult treatment panel (ATP) III criteria, meaning that individuals have 3 or more of the following characteristics:
- Waist circumference >102 cm for men or > 88 cm for women
- Triglycerides > 150 mg/d L
- HDL cholesterol < 40 mg/dL for men or < 50 mg/dL for women
- Blood pressure > 130/85 mm Hg or systolic ≥ 130 or diastolic ≥ 85*
- Fasting blood glucose > 100 mg/dL *Or taking blood pressure medications
Exclusion Criteria:
- Participants who do not fulfill the classification of metabolic syndrome, which means that they do not have 3 or more of the 5 characteristics previously mentioned
- Participants with a body mass index (BMI) > 40 kg/m2
- Current or past diagnosis of liver disease, renal disease, diabetes, cancer, stroke, heart disease, severe infectious disease, or autoimmune diseases (including but not limited to multiple sclerosis, lupus, and rheumatoid arthritis)
- Women who are pregnant, lactating, or planning to become pregnant
- Use of any glucose-lowering prescriptions or supplements, such as Sulfonylureas (Glucotrol, Amaryl, chlorpropamide, gliclazide, glimepiride, glipizide, glyburide), Thiazolidinediones (Avandia, ACTOS, rosiglitazone, pioglitazone), Meglitinides (Prandin, Starlix), Biguanides (Metformin), Alpha-glucosidase inhibitors (Precose, Glyset, acarbose, miglitol), Dipeptidyl peptidase (DPP)-4 inhibitors (Januvia, Onglyza, alogliptin, linagliptin, saxagliptin, sitagliptin), Glucagon-like peptide (GLP-1) antagonists (exenatide, liraglutide), Meglitinides (nateglinide, repaglinide), sodium glucose cotransporter (SGLT)-2 inhibitors (canagliflozin) or high dose chromium or cinnamon supplements
- Use of immunosuppressants, including azathioprine, cyclophosphamide, basiliximab, cyclosporine, everolimus, daclizumab, infliximab, mercaptopurine, methotrexate, muromonab-cluster of differentiation3 (CD3), mycophenolate, pimecrolimus, rituximab, tacrolimus, sirolimus, prednisone, methylprednisone, dexamethasone, hydrocortisone (not topical), or prednisolone
- Use of anticoagulants, including factor Xa inhibitors (rivaroxaban, apixaban), thrombin inhibitor (dabigatran), vitamin K antagonist (warfarin), heparin, low-molecular weight heparin, fondaparinux, or antiplatelets (aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticagrelor, ticlopidine)
- Use of other categories of drugs, including methadone, Suboxone, monoamine oxidase (MAO) inhibitors, or lithium.
- Use of any combination drug product containing any of the individual drugs listed above
- Participants who have been consistently taking vitamin, mineral, or multivitamin supplements prior to recruitment may be admitted into the study if they plan to maintain their current supplement program. However, subjects may not participate if they begin taking a new supplement during the 27-week study period.
- Fasting plasma triglycerides ≥ 500 mg/dL, glucose ≥ 126 mg/dL, or blood pressure > 145/100 mm Hg or systolic > 145 mm Hg or diastolic > 100 mm Hg

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02531334
United States, Connecticut | |
University of Connecticut | |
Storrs, Connecticut, United States, 06269 |
Principal Investigator: | Maria Luz Fernandez, PhD | University of Connecticut |
Responsible Party: | Maria Luz Fernandez, Professor, University of Connecticut |
ClinicalTrials.gov Identifier: | NCT02531334 |
Other Study ID Numbers: |
H14-278 |
First Posted: | August 24, 2015 Key Record Dates |
Last Update Posted: | October 10, 2018 |
Last Verified: | October 2018 |
Metabolic Syndrome Syndrome Disease Pathologic Processes |
Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |